Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast

Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. Patient biomarker status (e.g., BRAF, RAS, MSI-H/dMMR) and tumor location play a key role in guiding treatment selection. Immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo and Yervoy) and BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi) have recently emerged as novel options and will see robust uptake in eligible patients. Further personalization of treatment will ensure continued uptake of currently approved therapies over the 2020-2030 forecast period. We also expect several novel agents and combinations to impact the market and help address the high unmet need for additional and more-efficacious treatments.

QUESTIONS ANSWERED

  • How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?
  • What are key opinion leaders’ views on current and emerging therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?
  • Which pipeline products are poised to launch for colorectal cancer, and what unmet needs do they address?
  • What are the key drivers and constraints on the colorectal cancer therapy market, and how will the major markets evolve over the 10-year forecast period?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • Key updates
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
        • November 2021
        • October 2021
      • Q3 2021
        • September 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
    • Key findings
      • Colorectal cancer u2013 key findings
        • March 2021
        • February 2021
        • January 2021
    • Market outlook
      • Key findings
        • Market share of drug classes for colorectal cancer: 2020
        • Market share of drug classes for colorectal cancer: 2030
        • Drug-treatable population share and major-market sales share in colorectal cancer: 2020
        • Drug-treatable population share and major-market sales share in colorectal cancer: 2030
        • Population positioning of therapies in colorectal cancer
        • Colorectal cancer SWOT analysis
      • Market drivers and constraints
        • What factors are driving the market for colorectal cancer?
        • What factors are constraining the market for colorectal cancer?
        • Major-market sales of key drug classes for colorectal cancer over the 2020-2030 forecast period (millions of U.S. dollars)
        • Major-market sales of key drugs for colorectal cancer by brand/biosimilar: 2020-2030
      • Segment-specific trends
        • Patient-share dynamics of key players in stage III colon cancer, United States (2020-2030)
        • Patient-share dynamics of key players in stage IV first-line, left-sided, BRAF Wild-Type, RAS Wild-Type colorectal cancer, U.S. (2020-2030)
        • Patient-share dynamics of key players in stage IV first-line, right-sided, BRAF Wild-Type, RAS Wild-Type colorectal cancer, U.S. (2020-2030)
        • Patient-share dynamics of key players in stage IV first-line, BRAF Wild-Type, RAS-Mutant colorectal cancer, U.S. (2020-2030)
        • Patient-share dynamics of key players in stage IV first-line, BRAF-Mutant, RAS Wild-Type colorectal cancer, U.S. (2020-2030)
        • Second-line metastatic colorectal cancer
        • Patient-share dynamics of key players in stage IV second-line, left-sided, BRAF Wild-Type, RAS Wild-Type colorectal cancer, U.S. (2020-2030)
        • Patient-share dynamics of key players in stage IV second-line, right-rided, BRAF Wild-Type, RAS Wild-Type colorectal cancer, U.S. (2020-2030)
        • Patient-share dynamics of key players in stage IV second-line, BRAF Wild-Type, RAS-Mutant colorectal cancer, U.S. (2020-2030)
        • Patient-share dynamics of key players in stage IV second-line, BRAF-Mutant, RAS Wild-Type colorectal cancer, U.S. (2020-2030)
        • Patient-share dynamics of key players in stage IV third-line, left-sided, BRAF Wild-Type, RAS Wild-Type colorectal cancer, United States: 2020-2030
        • Patient-share dynamics of key players in stage IV third-line, right-sided, BRAF Wild-Type, RAS Wild-Type colorectal cancer, United States: 2020-2030
        • Patient-share dynamics of key players in stage IV third-line, BRAF Wild-Type, RAS-Mutant colorectal cancer, United States: 2020-2030
        • Patient-share dynamics of key players in stage IV third-line, BRAF-Mutant, RAS Wild-Type colorectal cancer, United States: 2020-2030
    • Forecast
      • Market forecast assumptions
      • Market forecast dashboard
    • Etiology & pathophysiology
      • Disease overview
        • Disease pathophysiology
          • Etiology
          • Risk factors for developing colorectal cancer
          • Pathophysiology
          • Proposed adenoma-carcinoma sequence model for colorectal cancer with chromosomal instability
        • Staging and classification
          • Staging of colorectal cancer
          • TNM classification of colorectal cancer
          • Modified Astler-Coller Dukes staging system vs. AJCC/UICC colorectal cancer (TNM) staging system
          • Symptoms according to tumor Location in colorectal cancer
          • Screening for colorectal cancer
          • Prognostic factors in colorectal cancer
        • Key pathways and drug targets
          • Drug targets for colorectal cancer
          • Select genes reportedly involved in colorectal cancer
      • Epidemiology
        • Key findings
          • Key updates
        • Epidemiology populations
          • Disease definition
          • Methods
          • Sources used for diagnosed incidence of colorectal cancer
          • Diagnosed incident cases of colorectal cancer: 2020-2030
          • Disease definition
          • Methods
          • Sources used for stage distribution of colorectal cancer
          • Diagnosed incident cases of colorectal cancer by stage distribution: 2020-2030
          • Definition
          • Methods
          • Sources used for recurrent incidence of colorectal cancer
          • Recurrent incident cases of colorectal cancer: 2020-2030
          • Colorectal cancer patient flow
          • Drug-treatable cases of colorectal cancer: 2020-2030
          • Drug-treated cases of colorectal cancer: 2020-2030
      • Current treatment
        • Key findings
          • Treatment goals
            • Key endpoints used in clinical trials for colorectal cancer
          • Key current therapies
            • Overview
            • Mechanism of action of key current drug classes used for colorectal cancer
            • Current treatments used for colorectal cancer
            • Market events impacting the use of key current therapies in colorectal cancer
            • Advantages and disadvantages of bevacizumab
            • Key results from select clinical trials investigating bevacizumab for the treatment of colorectal cancer
            • Expert insight: bevacizumab
            • Advantages and disadvantages of Zaltrap
            • Key results from select clinical trials investigating Zaltrap for the treatment of colorectal cancer
            • Expert insight: Zaltrap
            • Advantages and disadvantages of Cyramza
            • Key results from select clinical trials investigating Cyramza for the treatment of colorectal cancer
            • Ongoing clinical development of Cyramza
            • Key ongoing clinical trials of Cyramza in the treatment of colorectal cancer
            • Expert insight: Cyramza
            • Advantages and disadvantages of Stivarga
            • Key results from select clinical trials investigating Stivarga for the treatment of colorectal cancer
            • Expert insight: Stivarga
            • Advantages and disadvantages of Erbitux
            • Key results from select clinical trials investigating Erbitux for the treatment of colorectal cancer
            • Ongoing clinical development of Erbitux
            • Key ongoing clinical trials of Erbitux in the treatment of colorectal cancer
            • Expert insight: Erbitux
            • Advantages and disadvantages of Vectibix
            • Key results from select clinical trials investigating Vectibix for the treatment of colorectal cancer
            • Ongoing clinical development of Vectibix
            • Key ongoing clinical trials of Vectibix in the treatment of colorectal cancer
            • Expert insight: Vectibix
            • Key results from select clinical trials investigating Keytruda for the treatment of colorectal cancer
            • Ongoing clinical development of Keytruda
            • Key results from select clinical trials investigating Opdivo for the treatment of colorectal cancer
            • Ongoing clinical development of Opdivo
            • Key ongoing clinical trials of Opdivo in the treatment of colorectal cancer
            • Expert insight: Opdivo
            • Key results from select clinical trials investigating Braftovi for the treatment of colorectal cancer
            • Ongoing clinical development of Braftovi
            • Key ongoing clinical trials of Braftovi in the treatment of colorectal cancer
            • Expert insight: Braftovi
            • Advantages and disadvantages of Lonsurf
            • Key results from select clinical trials investigating Lonsurf for the treatment of colorectal cancer
            • Ongoing clinical development of Lonsurf
            • Key ongoing clinical trials of Lonsurf in the treatment of colorectal cancer
            • Expert insight: Lonsurf
            • Key results from select clinical trials investigating Perjeta and trastuzumab combination therapy for the treatment of colorectal cancer
            • Ongoing clinical development of Perjeta and trastuzumab combination therapy
            • Key ongoing clinical trials of Perjeta and trastuzumab combination therapy in the treatment of colorectal cancer
          • Medical practice
            • Stage II/III colon cancer
            • Stage II/III rectal cancer
            • Treatment of colorectal cancer with resectable liver metastases
            • Second-line treatment of metastatic colorectal cancer
            • Third- and later-line treatment of metastatic colorectal cancer
            • Patient characteristics influencing drug selection in colorectal cancer
            • Treatment decision tree for stage II/III colon and rectal cancer: G7
            • Treatment decision tree for stage IV colorectal cancer: United States
            • Treatment decision tree for stage IV colorectal cancer: France, Germany, Italy, and Spain
            • Treatment decision tree for stage IV colorectal cancer: United Kingdom
            • Treatment decision tree for stage IV colorectal cancer: Japan
        • Unmet need overview
          • Current and future attainment of unmet needs in colorectal cancer
          • Top unmet needs in colorectal cancer: current and future attainment
          • Expert insights: unmet need in colorectal cancer
        • Emerging therapies
          • Key findings
            • Key emerging therapies
              • Key therapies in development for colorectal cancer
              • Estimated market authorization dates of key emerging therapies for the treatment of colorectal cancer
              • Key results from select clinical trials investigating fruquintinib for the treatment of colorectal cancer
              • Key ongoing clinical trials of fruquintinib in the treatment of colorectal cancer
              • Analysis of the clinical development program for fruquintinib
              • Expert insight: fruquintinib
              • Expectations for market authorization and sales opportunity of fruquintinib in colorectal cancer
              • Key results from select clinical trials investigating Lenvima for the treatment of colorectal cancer
              • Key ongoing clinical trials of Lenvima in the treatment of colorectal cancer
              • Analysis of the clinical development program for Lenvima
              • Expert insight: Lenvima
              • Expectations for market authorization and sales opportunity of Lenvima in colorectal cancer
              • Key results from select clinical trials investigating adagrasib for the treatment of colorectal cancer
              • Key ongoing clinical trials of adagrasib in the treatment of colorectal cancer
              • Analysis of the clinical development program for adagrasib
              • Expert insight: adagrasib
              • Expectations for market authorization and sales opportunity of adagrasib in colorectal cancer
              • Lumakras / Lumykras
              • Key results from select clinical trials investigating Lumakras / Lumykras for the treatment of colorectal cancer
              • Ongoing clinical development of Lumakras / Lumykras
              • Key ongoing clinical trials of Lumakras / Lumykras in the treatment of colorectal cancer
              • Expectations for market authorization and sales opportunity of Lumakras / Lumykras in colorectal cancer
              • Key results from select clinical trials investigating Tecentriq for the treatment of colorectal cancer
              • Key ongoing clinical trials of Tecentriq in the treatment of colorectal cancer
              • Analysis of the clinical development program for Tecentriq
              • Expert insight: Tecentriq
              • Expectations for market authorization and sales opportunity of Tecentriq in colorectal cancer
              • Key ongoing clinical trials of Bavencio in the treatment of colorectal cancer
              • Analysis of the clinical development program for Bavencio
              • Expert insight: Bavencio
              • Expectations for market authorization and sales opportunity for Bavencio in colorectal cancer
              • Key results from select clinical trials investigating the Favezelimab / Keytruda fixed-dose combination for the treatment of colorectal cancer
              • Key ongoing clinical trials of Favezelimab / Keytruda fixed-dose combination in the treatment of colorectal cancer
              • Analysis of the clinical development program for Favezelimab / Keytruda fixed-dose combination
              • Expectations for market authorization and sales opportunity for Favezelimab / Keytruda fixed-dose combination in colorectal cancer
              • Key results from select clinical trials investigating OncoVAX for the treatment of colorectal cancer
              • Key ongoing clinical trials of OncoVAX in the treatment of colorectal cancer
              • Analysis of the clinical development program for OncoVAX
              • Expert insight: OncoVAX
              • Expectations for market authorization and sales opportunity for OncoVAX in colorectal cancer
              • Key results from select clinical trials investigating arfolitixorin for the treatment of colorectal cancer
              • Key ongoing clinical trials of arfolitixorin in the treatment of colorectal cancer
              • Analysis of the clinical development program for arfolitixorin
              • Expectations for market authorization and sales opportunity of arfolitixorin in colorectal cancer
              • Key results from select clinical trials investigating Lynparza for the treatment of colorectal cancer
              • Key ongoing clinical trials of Lynparza in the treatment of colorectal cancer
              • Analysis of the clinical development program for Lynparza
              • Expert insight: Lynparza
              • Expectations for market authorization and sales opportunity of Lynparza in colorectal cancer
              • Key results from select clinical trials investigating Tukysa for the treatment of colorectal cancer
              • Key ongoing clinical trials of Tukysa in the treatment of colorectal cancer
              • Analysis of the clinical development program for Tukysa
              • Expert insight: Tukysa
              • Expectations for market authorization and sales opportunity of Tukysa in colorectal cancer
            • Early-phase pipeline analysis
              • Select compounds in early-phase development for colorectal cancer
          • Access & reimbursement overview
            • Region-specific reimbursement practices
              • Key market access considerations in colorectal cancer: United States
              • General reimbursement environment: United States
              • Key market access considerations in colorectal cancer: EU5
              • General reimbursement environment: EU5
              • Key market access considerations in colorectal cancer: Japan
              • General reimbursement environment: Japan
          • Appendix
            • Colorectal cancer bibliography